Table 2. Provider continuity in the year prior to diagnosis of advanced lung cancer and end-of-life care.
End of life care measures,% yes | |||||
Continuity Measure | N | Hospitalized1 | ICU1 | Chemotherapy1 | Hospice2 |
All Subjects | 69427 | 50.4 | 13.0 | 12.8 | 45.6 |
Saw a PCP | |||||
No | 22106 | 47.3 | 12.3 | 11.1 | 41.4 |
Yes | 47321 | 51.8 | 13.3 | 13.6 | 47.6 |
Number of PCPs seen | |||||
0 | 22106 | 47.3 | 12.3 | 11.1 | 41.4 |
1 | 33289 | 51.6 | 13.2 | 13.7 | 46.9 |
>1 | 14032 | 52.4 | 13.7 | 13.3 | 49.3 |
Total number of visits to PCP | |||||
0 | 22106 | 47.3 | 12.3 | 11.1 | 41.4 |
1–3 | 20193 | 50.0 | 12.4 | 14.0 | 48.2 |
4–7 | 17229 | 52.5 | 13.0 | 13.8 | 48.2 |
>7 | 9899 | 54.3 | 15.9 | 12.3 | 45.2 |
Number of visits to an assigned PCP (N = 47321) | |||||
1–3 | 23328 | 50.3 | 12.5 | 14.0 | 48.6 |
4–7 | 16445 | 52.4 | 13.3 | 13.7 | 48.0 |
>7 | 7548 | 55.0 | 16.3 | 12.2 | 43.5 |
Time exposure method continuity of PCP3 | |||||
No | 25745 | 47.8 | 12.2 | 11.5 | 42.2 |
Yes | 43682 | 51.9 | 13.5 | 13.6 | 47.6 |
Saw any provider | |||||
No | 13300 | 43.3 | 10.8 | 9.2 | 39.7 |
Yes | 56127 | 52.1 | 13.5 | 13.6 | 47.0 |
Number of any provider seen | |||||
0 | 13300 | 43.3 | 10.8 | 9.2 | 39.7 |
1 | 21880 | 50.5 | 12.5 | 12.4 | 45.4 |
>1 | 34247 | 53.1 | 14.2 | 14.5 | 48.0 |
Total number of visits to any provider | |||||
0 | 13300 | 43.3 | 10.8 | 9.2 | 39.7 |
1–3 | 17226 | 48.9 | 11.8 | 13.1 | 47.1 |
4–7 | 18728 | 51.7 | 12.6 | 13.7 | 48.4 |
>7 | 20173 | 55.0 | 15.9 | 14.0 | 45.7 |
Number of Visits to a assigned provider (N = 56127) | |||||
1–3 | 25325 | 49.8 | 12.1 | 13.7 | 48.3 |
4–7 | 20875 | 53.0 | 13.7 | 13.9 | 47.6 |
>7 | 9927 | 55.9 | 16.7 | 12.8 | 42.7 |
Time exposure method continuity of any provider3 | |||||
No | 16727 | 44.4 | 10.9 | 10.2 | 40.8 |
Yes | 52700 | 52.3 | 13.7 | 13.6 | 47.1 |
1 = in last month of life.
2 = in last week of life.
ICU, intensive care unit; PCP, primary care physician.
3 = Time exposure method of continuity is defined as having visited the same physician twice within any eight months over the two years prior to the diagnosis of lung cancer